Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cairoli, R
Right arrow Articles by Morra, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cairoli, R
Right arrow Articles by Morra, E
Haematologica, Vol 89, Issue 3, 361-363
Copyright © 2004 by Ferrata Storti Foundation

Letter

High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation

R Cairoli, G Grillo, A Tedeschi, G D'Avanzo, P Marenco, and E Morra

We report a high incidence of neutropenia in patients treated with rituximab prior to and following autologous stem cell transplantation (ASCT). Fourteen patients with follicular or mantle-cell lymphoma were treated with high dose (HD) therapy followed by an in vivo-purged autologous graft.


This article has been cited by other articles:


Home page
 JCOHome page
C. Tarella, M. Zanni, M. Magni, F. Benedetti, C. Patti, T. Barbui, A. Pileri, M. Boccadoro, F. Ciceri, A. Gallamini, et al.
Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey
J. Clin. Oncol., July 1, 2008; 26(19): 3166 - 3175.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
B. Terrier, M. Ittah, L. Tourneur, F. Louache, V. Soumelis, F. Lavie, N. Casadevall, S. Candon, A. Hummel, X. Mariette, et al.
Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery
Haematologica, February 1, 2007; 92(2): e20 - e23.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E Nitta, K Izutsu, T Sato, Y Ota, K Takeuchi, A Kamijo, K Takahashi, K Oshima, Y Kanda, S Chiba, et al.
A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study
Ann. Onc., February 1, 2007; 18(2): 364 - 369.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.